Brief: Nanoviricides Says First Drug Candidate Is On Track For Human Clinical Trials
05/08/2019 12:19
Aug 5 (Reuters) - NanoViricides Inc NNVC.A :
* NANOVIRICIDES REPORTS ITS FIRST DRUG CANDIDATE IS ON TRACK
WITH
GLP SAFETY/TOXICOLOGY STUDIES TOWARD HUMAN CLINICAL TRIALS
* NANOVIRICIDES - NV-HHV-101 FOUND TO BE SAFE & WELL
TOLERATED IN
CLINICAL OBSERVATION PORTION OF GLP SAFETY/TOXICOLOGY STUDY OF
NV-HHV-101 AS DERMAL TREATMENT
* NANOVIRICIDES - INTEND TO FILE IND WITH US FDA SOON AFTER
COMPLETION OF GLP SAFETY/TOXICOLOGY STUDIES, RECEIPT OF FINAL
REPORTS FROM PERFORMING AGENCIES
Source text for Eikon: ID:nPn11BRXha
Further company coverage: NNVC.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NanoViricides,
See all newsExplainer: What do we know about the Bundibugyo strain of the Ebola virus?
Brief: anoViricides Signs Agreement for Orphan Drug Strategy of NV-387 for Mpox, Smallpox, and Measles
Brief: Nanoviricides Says NV-387 Shows Activity Against Measles Virus In Humanized Animal Model
Brief: Nanoviricides Co's Business Not Affected By Tariff Policies Of Us Government Or Corresponding Retaliatory Policies Of Other Governments
Brief: Nanoviricides Obtained Right Of First Refusal For All Antiviral Drug Developments